Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BRACE trial

- PMLiVE

J&J’s COVID-19 booster shows 85% effectiveness in preventing hospitalisation for COVID-19 in study

The Sisonke study was done in South Africa while Omicron was the dominant variant

- PMLiVE

Pfizer/BioNTech receives expanded authorisation from the FDA for its COVID-19 booster

The booster dose of the companies’ COVID-19 vaccine is now authorised to include individuals aged 12 years and older

Lesson Learned from the Pandemic

Tom Hsu, VP of Specialty Medicine at Bayer Canada, talks about how he got to where he is today and his experience working for Bayer in China and how that...

Impetus Digital

- PMLiVE

US prefers mRNA COVID-19 vaccines over J&J

Citing concerns over blood clots, Americans are now advised that should get the Pfizer-BioNTech or Moderna vaccines in preference to Johnson and Johnson vaccine

- PMLiVE

Sanofi/GSK vaccine boosts immune response

The vaccine boosted neutralising antibodies by 9 to 43-fold regardless of which vaccine was given as a primary course

- PMLiVE

South Africa releases first real-world evidence for Omicron

Briefing members of the UK parliament, the head of South Africa's Medical Association, Dr Angelique Coetzee, said the risk of severe COVID-19 was 29% lower with Omicron than Delta

- PMLiVE

UK supercharges booster programme over Omicron

The UK is to offer all vaccinated adults a COVID-19 booster to counter a ‘tidal wave of Omicron’ this winter, as evidence mounts of lower immunity from vaccines

- PMLiVE

FDA approves first pre-exposure prophylactic against COVID-19

AstraZeneca’s (AZ) Evushield offers long-acting protection against COVID-19 in people who are either unable to receive or mount an insufficient response to a vaccine

- PMLiVE

Omicron rise prompts tougher measures in England

The Omicron variant is spreading so rapidly in the UK that government experts predict 1,000-2,000 hospitalisations per day, prompting stricter control measures in England

- PMLiVE

Pfizer/BioNTech promote booster against Omicron

Preliminary laboratory studies suggest three doses of the Pfizer/BioNTech vaccine neutralises Omicron to the same extent as two doses neutralise the original, ‘wild-type’ SARS-CoV-2

- PMLiVE

Roche’s Actemra approved for severe COVID-19 in Europe

The monoclonal antibody previously used to treat inflammatory conditions such as rheumatoid arthritis is already being used in the US and Australia

- PMLiVE

Mix-and-match COVID-19 vaccines may be more effective

A small study shows a booster shot of J&J’s vaccine six months after a primary course of the Pfizer/BioNTech vaccine may offer more protection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links